Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: ACLX) | Delayed: 115.07 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $115.07 | 52 Week High | $ | |||
| Open | $115.07 | 52 Week Low | $ | |||
| Day High | $115.07 | P/E | N/A | |||
| Day Low | $115.07 | EPS | $ | |||
| Volume | 751 | |||||
| Gilead Sciences (NASDAQ: GILD) | Delayed: 156.04 -1.15 (0.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $157.19 | 52 Week High | $108.63 | |||
| Open | $156.47 | 52 Week Low | $71.39 | |||
| Day High | $157.65 | P/E | 86.21 | |||
| Day Low | $155.76 | EPS | $1.81 | |||
| Volume | 6,070,932 | |||||
